JAMA Neurol:卒中后延迟再灌注的时间可降低患者的治疗效果

2015-12-23 MedSci MedSci原创

据发表于JAMA Neurology的一项新的研究表明,中风后血流恢复延迟可影响动脉内溶栓的治疗效果,降低患者获得较好预后的机会。

据发表于JAMA Neurology的一项新的研究表明,中风后血流恢复延迟可影响动脉内溶栓的治疗效果,降低患者获得较好预后的机会。

时间是预测中风患者治疗后临床结果的一个重要的预测因子,也是预测患者治疗效果的一个重要预测因子。

Diederik W.J. Dippel博士及其同事探究了从中风到开始接受治疗的时间以及从中风到再灌注的时间对介入治疗效果(IAT)的影响。IAT包括在动脉堵塞的水平插入导管,可导入溶栓药物或机械切除血凝块或二者同时进行。

该随机临床试验共纳入了500名患者,其中分配233名患者接受IAT治疗。研究人员对比了接受IAT(大多是用可回收支架)治疗与未接受IAT治疗的差异。定义开始治疗时间为从中风症状出现到腹股沟穿刺(TOG)以放置导管的时间。定义治疗开始到再灌注的时间(TOR)为重新疏通堵塞的血管的时间或未能成功实现再灌注患者治疗结束时的时间。所有患者均接受常规治疗,包括静脉注射治疗(IVT)导入溶栓药物。

500名患者中,TOG中位值为260分钟, TOR中位值为340分钟。233名分配至接受IAT治疗的患者中有17名患者未按约进行干预治疗;25名患者在卒中发病后三小时内开始接受治疗,96名患者在卒中发生后3-4.5小时内接受治疗,95名患者是在卒中发生4.5小时后才开始接受治疗,其中19名患者是在卒中发生6小时后才开始接受治疗。

结果发现,TOR与治疗效果之间存在关联,但是并没有观察到TOG与治疗效果之间存在明显的关联。作者认为,再灌注时间每延迟6小时便会降低患者6%出现较好结局的机会。

最后,研究人员总结道,“这项研究强调了减少急性缺血性卒中患者延迟接受IAT治疗的时间的重要性。绝对治疗的效果及其随时间延长而降低的程度均大于静脉注射治疗。…最重要的是,我们的研究结果表明,急性缺血性卒中患者应立即进行诊断检查,且在颅内动脉血管闭塞时立即接受IAT治疗”。

原始出处:

Chances of good outcome after stroke reduced by delays in restoring blood flow. Science Daily, December 21, 2015.

Diederik W. J. Dippel, MD, PhD et al. Time to Reperfusion and Treatment Effect for Acute Ischemic Stroke: A Randomized Clinical Trial. JAMA, December 2015 DOI:10.1001/jamaneurol.2015.3886

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1999620, encodeId=2628199962004, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Jun 05 12:39:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671221, encodeId=fd0516e122198, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Thu Dec 24 02:39:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893904, encodeId=afaf189390405, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Feb 02 23:39:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47523, encodeId=7bc24e5231e, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Thu Dec 24 19:18:00 CST 2015, time=2015-12-24, status=1, ipAttribution=)]
    2016-06-05 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=1999620, encodeId=2628199962004, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Jun 05 12:39:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671221, encodeId=fd0516e122198, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Thu Dec 24 02:39:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893904, encodeId=afaf189390405, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Feb 02 23:39:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47523, encodeId=7bc24e5231e, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Thu Dec 24 19:18:00 CST 2015, time=2015-12-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1999620, encodeId=2628199962004, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Jun 05 12:39:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671221, encodeId=fd0516e122198, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Thu Dec 24 02:39:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893904, encodeId=afaf189390405, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Feb 02 23:39:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47523, encodeId=7bc24e5231e, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Thu Dec 24 19:18:00 CST 2015, time=2015-12-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1999620, encodeId=2628199962004, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Jun 05 12:39:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671221, encodeId=fd0516e122198, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Thu Dec 24 02:39:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893904, encodeId=afaf189390405, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Feb 02 23:39:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47523, encodeId=7bc24e5231e, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Thu Dec 24 19:18:00 CST 2015, time=2015-12-24, status=1, ipAttribution=)]
    2015-12-24 zhuzhuba1

    0

相关资讯

Stroke:BMI和老年房颤患者不良预后的研究(AMADEUS试验)

背景和目的:肥胖与房颤患者心血管风险增高相关,但是对老年房颤患者心血管风险发生的了解较少。方法:对AMADEUS试验中的数据进行hoc 分析。结果:研究者研究了1588名老年患者,将其分为正常BMI组(BMI,18.5-25Kg/m2;n = 515 [ 32.4% ]),超重组(BMI 25-30Kg/m2;n = 711 [ 44.8% ])及肥胖组(BMI≥30Kg/m2;n = 362 [

Stroke:哪些卒中幸存者发生抑郁风险较高?

背景和目的:尽管卒中后抑郁较常见,抑郁发生是否存在种族差异尚不清楚。因此,研究者在多种族卒中队列研究中调查种族和抑郁的关系。方法:在社区居住的城市脑卒中/短暂性脑缺血发作的患者中进行的预防卒中再发的研究中,调查患者基线抑郁和功能状态的量表,人口学资料,共发病和社会经济状态。结果:包括556名受试者,平均年龄64岁。绝大多数是黑人(44%)和拉丁美洲人(42%)和女性(60%),招募的受试者最后一次

Stroke:NHISS完整量表比简短量表更有效评估卒中患者严重程度

背景和目的:已有人批判15项美国国立卫生卒中量表(NHISS)的复杂性和变异性,已经提出了简短的版本。这项研究旨在比较原始版本和3个简短版本之间的测试效能,这三个原始版本分别为11项,8项和5项。方法:对国际双盲随机对照试验的数据进行分析,这个试验调查中度严重(CHIMES)的缺血性卒中患者,卒中康复的MLC600效度。应用回归分析,比较量表的区分度和变化的反应性,NHISS分数和mRS,简明精神

Stroke:卒中后认知功能受损的筛查手段有限

中风后认知评估可以通过专为家庭或照顾者制定的标准化调查问卷获得。研究人员试图描述这种已报告为基础的评估痴呆/多脑卒中认知障碍中风诊断的测试准确性。

J Am Heart Assoc:控制血压可减少房颤患者卒中的发生(ARISTOTLE研究)

背景:房颤(AF)和高血压是卒中发生的高危因素。以往研究表明。存在高血压史(不管血压控制情况)的房颤患者,及血压升高的患者卒中发生的风险增加。研究者评估了高血压及高血压控制对临床预后的相关性。方法和结果:ARISTOTLE(n = 18201),评估血压确定需要治疗的高血压及进入研究和实验过程中血压升高(收缩压≥140及/或舒张压≥90mm Hg)。血压为时间依赖协变量,应用Cox比例风险模型计算

PLoS One:垂体腺瘤卒中的危险因素研究进展

垂体腺瘤卒中(PA)是指垂体腺瘤出血或梗死引起的突发性头痛、呕吐、视力下降甚至意识障碍等急性综合征,多数发生于未经诊断的垂体腺瘤患者。目前有关PA的研究较少,国内没有统一的PA诊断标准和治疗预后的随机对照研究。上海华山医院内分泌和代谢科的Xiaoming Zhu等报道该院神经外科和垂体腺瘤研究中心李士其教授和叶红英教授等对PA的危险因素回顾性临床研究结果,发表于2015年9月25日的《PLoS O